SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

(NASDAQ: SCYX), a clinical-stage biotechnology company advancing novel therapies for severe rare diseases, today announced initiation of a Phase 1 study of SCY-770, a first-in-class, potent and direct ...
Nature

Autosomal Dominant Polycystic Kidney Disease Management and Outcomes

Autosomal dominant polycystic kidney disease (ADPKD) is a hereditary disorder characterised by progressive formation and enlargement of fluid-filled cysts in the renal parenchyma, most commonly due to ...